植田 真一郎 (ウエダ シンイチロウ)

Ueda Shinichiro

写真a

職名

教授

科研費研究者番号

80285105

現在の所属組織 【 表示 / 非表示

  • 専任   琉球大学   医学研究科   教授  

留学歴 【 表示 / 非表示

  • 1991年10月
    -
    1996年07月

    Department of Medicine& Therapeutics Western Infirmary,University of Glasgow,Scotland, UK  

取得学位 【 表示 / 非表示

  • 横浜市立大学 -  医学博士  その他 / その他

職歴 【 表示 / 非表示

  • 2001年12月
    -
    継続中

      琉球大学 医学研究科 教授  

研究キーワード 【 表示 / 非表示

  • ヒト血管内皮機能

  • 平滑筋機能,心血管薬薬効評価のための代替エンドポイントの開発,降圧利尿薬ランダム化臨床試験,代謝症候群における血管機能

  • インスリン感受性への治療介入と評価

論文 【 表示 / 非表示

  • Association of schizophrenia with fracture-related femoral neck displacement: A cross-sectional retrospective study.

    Yukiyo Inoue, Akihiro Tokushige, Takeshi Kinjyo, Shinichiro Ueda

    PCN reports : psychiatry and clinical neurosciences   3 ( 2 ) e195   2024年06月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    AIM: Fracture-related femoral neck displacement is more likely in patients with schizophrenia because of delayed diagnosis, as these patients frequently have less severe fracture-associated subjective symptoms. This study aimed to investigate the association of schizophrenia with the risk of fracture-related femoral neck displacement in hospitalized patients. METHODS: We retrospectively analyzed the medical records of patients with femoral neck fractures treated between April 2013 and March 2018 at a single institution. Multivariate logistic regression was used to explore the relationship between schizophrenia and fracture-related femoral neck displacement after adjusting for risk factors. RESULTS: We compared 30 and 194 patients with and without schizophrenia, respectively. The prevalence of fracture-related displacement was 80.0% in patients with schizophrenia and 62.4% in the controls (p = 0.06). After adjusting for confounding variables, schizophrenia significantly correlated with fracture-related femoral neck displacement (odds ratio: 4.74, 95% confidence interval: 1.09-20.60, p = 0.0378). CONCLUSIONS: Schizophrenia is associated with a higher risk of severe femoral neck fracture. To improve outcomes and alleviate the societal burden of femoral neck fractures, early radiographic assessment and surgical intervention for femoral fractures are essential for patients with schizophrenia, even in those without pain symptoms.

  • Analysis of in-hospital deaths in patients with critical limb ischemia necessitating invasive treatments: based on a Japanese nationwide database

    Iwata, K; Nitta, M; Kaneko, M; Fushimi, K; Ueda, S; Shimizu, S

    CARDIOVASCULAR INTERVENTION AND THERAPEUTICS ( Cardiovascular Intervention and Therapeutics )    2024年04月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

  • Factors associated with carotid intima-media thickness progression in patients with asymptomatic hyperuricemia: insights from the PRIZE study

    Saito Y.

    Scientific Reports ( Scientific Reports )  13 ( 1 )   2023年12月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

  • Agile 3+and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver-related events in nonalcoholic fatty liver disease

    Miura, K; Hayashi, H; Kamada, Y; Fujii, H; Takahashi, H; Oeda, S; Iwaki, M; Kawaguchi, T; Tomita, E; Yoneda, M; Tokushige, A; Ueda, S; Aishima, S; Sumida, Y; Nakajima, A; Okanoue, T

    HEPATOLOGY RESEARCH ( Hepatology Research )  53 ( 10 ) 978 - 988   2023年10月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    AIM: The noninvasive tests (NITs) Agile 3+ and Agile 4 effectively identify patients with nonalcoholic fatty liver disease (NAFLD) complicated with advanced fibrosis (F3-4) and cirrhosis (F4), respectively. Little information is available on associations between Agile scores and intra-/extrahepatic events. The aim of this study was to determine the predictive performance of Agile scores for intra-/extrahepatic events in Asian patients with biopsy-proven NAFLD. METHODS: We undertook a retrospective multicenter cohort study to investigate associations between intra-/extrahepatic events and two Agile scores, Agile 3+ and Agile 4. The scores were obtained by combining clinical parameters and liver stiffness measurement using transient elastography. RESULTS: Among 403 enrolled patients, 11 had liver-related events (LREs), including seven with hepatocellular carcinoma (HCC). The incidence of LREs and HCC showed a stepwise increase in the advanced fibrosis group (F3-4), Agile 3+ rule-in (F3-4, highly suspected), and Agile 4 rule-in (F4, highly suspected) groups, compared to their counterparts. Hazard ratios for LREs in the advanced fibrosis group, Agile 3+ rule-in, and Agile 4 rule-in groups were 4.05 (p = 0.03), 23.5 (p = 0.003), and 45.5 (p < 0.001), respectively. The predictive performance results for Agile 3+ and Agile 4 were 0.780 and 0.866, respectively, which were higher than for fibrosis (0.595). Unlike for LREs, Agile scores failed to identify patients with extrahepatic events, including cardiovascular events and extrahepatic cancer. CONCLUSIONS: Agile 3+ and Agile 4 scores are excellent NITs for predicting LREs in patients with NAFLD, possibly without histological assessment.

  • Comparison of the Quality of Phase Ⅲ Non-commercial Clinical Trials in Japan, the United States, and the United Kingdom before the Implementation of the New Japanese Clinical Trials Act

    Yamauchi S.

    臨床薬理 ( 一般社団法人 日本臨床薬理学会 )  54 ( 3 ) 95 - 101   2023年05月 [ 査読有り ]

    掲載種別: 研究論文(学術雑誌)

     概要を見る

    <p>Recent research misconduct, represented by the valsartan scandal, has raised questions about the quality of non-commercial trials not for regulatory approval in Japan. Unlike in the US and Europe, non-commercial clinical trials are not regulated by law in Japan, which was believed to be a reason why quality could not be guaranteed. However, until now, few studies have compared the quality of clinical studies among countries. In this study, the quality of Japanese non-commercial phase Ⅲ trials before the implementation of the Clinical Trials Act (CTA) in 2018 was compared with Western non-commercial trials registered in the database using study design as quality indicators. The study found a lower proportion of randomized, controlled trials (RCTs) (70% in Japan, 89% in the US, and 88% in the UK) and fewer blinded designs (46% in Japan, 59% in the US, and 52% in the UK) in non-commercial trials in Japan. Single-arm trials not for either cancer or rare diseases, which are usually considered low quality because of a lack of fair comparison, were more common in Japan (82%) than in the US (76%) and the UK (50%). In terms of endpoint setting, most non-commercial trials in Japan had surrogate endpoints, with only a few trials using true endpoints (5%) compared to the US (24%) and the UK (40%). A comparison of these quality indicators in Japanese non-commercial trials before and after the CTA implementation showed no increases in the proportion of RCT and blinded designs, but an increase in the proportion of trials using true endpoints and appropriate use of single-arm design. In conclusion, the lack of legal regulation in Japan may have indirectly affected the quality of non-commercial phase Ⅲ trials in Japan at the time. Implementation of the CTA has contributed to some quality improvements, but the effect is limited at present. </p>

全件表示 >>

著書 【 表示 / 非表示

MISC(その他業績・査読無し論文等) 【 表示 / 非表示

全件表示 >>

研究発表等の成果普及活動 【 表示 / 非表示

全件表示 >>

科研費獲得情報 【 表示 / 非表示

  • 白血球活性化抑制による動脈硬化治療を目指した臨床薬理学研究

    基盤研究(C)

    課題番号: 15K08592

    研究期間: 2015年04月  -  2018年03月 

    代表者: 植田 真一郎  研究分担者: 浦田 秀則 福岡大学, 医学部, 教授 (30289524) 森本 剛 兵庫医科大学, 医学部, 教授 (30378640)

    直接経費: 3,800,000(円)  間接経費: 1,140,000(円)  金額合計: 4,940,000(円)

  • 80歳以上の高齢者を対象とした大腿骨近位部骨折の発生要因を明らかにするための研究

    基盤研究(C)

    課題番号: 25462377

    研究期間: 2013年04月  -  2016年03月 

    代表者: 金谷 文則, 普天間 朝上, 植田 真一郎 

    直接経費: 3,300,000(円)  間接経費: 4,290,000(円)  金額合計: 990,000(円)

     概要を見る

    沖縄県内の老人保健施設において、2010年~14年の間に新規入所した後期高齢者1930例のカルテから大腿骨近位部骨折発生の関連因子を後見的に調査した。骨折発生率は3.4%で、7,8月に発生が多くみられた。介護度の低い介護1および2、障害高齢者の自立度で自立度が高いランクJおよびA、日常生活が比較的自立しているBarthel indexが60以上で骨折リスクが高かった。また認知症高齢者の日常生活自立度では認知症が重度のランク3aおよび3bで骨折リスクが高い傾向があった。対側の大腿骨近位部骨折の既往がある方に骨折発生リスクが高かった。

  • 心血管系バイオマーカーとヒト薬効評価実験系に関する臨床薬理学的研究

    基盤研究(C)

    課題番号: 22590503

    研究期間: 2010年04月  -  2012年03月 

    代表者: 植田 真一郎  研究分担者: 浦田 秀則 福岡大学, 筑紫病院, 教授 (30289524) 松岡 秀洋 久留米大学, 医学部, 教授 (80248393)

    直接経費: 3,300,000(円)  間接経費: 990,000(円)  金額合計: 4,290,000(円)

  • 心血管薬の薬効評価に資するヒト実験系と臨床試験でのサロゲートマーカーの開発評価

    基盤研究(C)

    課題番号: 19590541

    研究期間: 2007年  -  2009年 

    代表者: 植田 真一郎 

    直接経費: 1,200,000(円)  間接経費: 360,000(円)  金額合計: 1,560,000(円)

  • 心血管薬の薬効評価システムの開発と臨床試験に向けた代替エンドポイントの評価

    基盤研究(C)

    課題番号: 16590439

    研究期間: 2004年  -  2006年 

    代表者: 植田 真一郎 

    直接経費: 1,200,000(円)  金額合計: 1,200,000(円)

その他研究費獲得情報 【 表示 / 非表示

  • 臨床研究プロフェッショナル育成プログラムの作成

    研究費種類: 公的研究費(省庁・独法・大学等)  参画方法: 研究代表者

    研究種別: 研究助成  事業名: 中央IRB推進事業

    研究期間: 2020年04月  -  2021年03月 

    代表者: 植田 真一郎  連携研究者: 植田真一郎 山中竹春 志賀剛 吉田雅幸 池原由美  資金配分機関: 日本医療研究開発機構